Rimonabant Acomplia

An announcement was made about Sanofi-Aventis.This refears to  the launch of Acomplia (rimonabant), a  new  medication that treats  abdominally obese persons which presents cardio metabolic risk cluster.

This medication was approved from the European Medicines Evaluation Agency (EMEA) in order  to be used,but combined  with diet and sport and it’s ment to the treat  obesity with cardio metabolic risk cluster.People can buy Acomplia  already in more that 15 European states, including very important states like Germany and the UK.

This  new obesity drug can reduce very much the  blood sugar levels in persons which have type 2 diabetes and in the same time it helps  this persons to reduce their body weight. Acomplia way of working is  by select and block the  receptors that are located in the brain and in peripheral organs important in glucose and lipid metabolism,and that  includes the liver, gastrointestinal tract, adipose tissue, and muscle. The medication is decreasing the over activity of the endocannabinoid system (EC system). The EC system was a short time ago characterized as a physiological system that includes receptors such as the CB¹ receptor, and scienties think that in order  to play an very important role in controlling energy balance ,in regulating body weight and glucose and lipid metabolism.So it’s ok for people to use and buy acomplia.

Buy Acomplia a really good Diet Pill

Acomplia is a new medication which helps people to lose weight, rimonabant (also named Acomplia), and it is helping also patiens with diabetes type 2. It helps people lose pounds and meanwhile it  makes patiens have a much better blood sugar levels,so  science people say. The buy of acomplia is being approved and tested in Europe. Despite that fact, Acomplia hasn’t been approved for use in the United States,at least for now. This discovering tell us that acomplia can be used as a new alternative in treating diabetes,despite that other drugs have failed and couldn’t improve people health. In one study, Andre Thomson, and another scientice people had a look on the  effects of acomplia in more that 1,000 persons with a very hard to controll type 2 diabetes.

All the people that participated had obesity or overweight and other treatment with other drugs failed. Those people were given a low-calorie diet plan and werw advised to be more physically active. They also toke  acomplia at a dose of either 5 milligrams or 20 milligrams per day, or a placebo.Results were amaizing.So ,you can buy acomplia and use it and not worry about the result,becouse they will surprise you.

Acomplia(Rimonabant) is a medication that treats very well obesity by making people to eat less has been launched in the UK.

Acomplia(Rimonabant) is the first drug that can reduce  the body’s appetite, metabolism and energy that we can use. Trials have proved that it can reduce weight by a tenth.

UK Experts think that acomplia(rimonabant) does  not  have the property to replace healthy food and sport exercise.

In this country , statistics showed that one in five men and a quarter of women are obese.

Price

The cost of acomplia(rimonabant) in very big,about over £55 for a month’s treatment and this it may go to a  cost of billions of pounds of money for the NHS.

The drug is going to be assessed by NHS advisers the National Institute for Health and Clinical Excellence.

The review is going to be given sometime in the next two years and NHS bosses warned the public that is not good to expect its widespread use right away.

The chief executive of the NHS Confederation,Gill Morgan, said primary care trusts may be reluctant to prescribe the medication despite of NICE guidance.

“PCTs receive a fixed sum of money to put to the diposition of their local community all the services and have to asume very hard decisions on competing priorities.”

Also she said that weight loss was “predominantly about diet and sport exercise”.

The producer of acomplia(rimonabant), Sanofi Aventis, has said that the drug represents the best value for money when set against the £7bn per year cost of living behind obesity.

In a lot of trials that were involving more than 6,000 patients in the US and Europe, a quarter lost more than 10% of their initial body weight only in a year. About half lost more than 5% in the same period.

Some other anti-obesity drugs are available at this moment, but acomplia (rimonabant) is the only one to target the endocannabinoid system, whichis responsible with the body’s appetite.

Side effects of acomplia(rimonabant) in some patients are some like nausea, dizziness and anxiety.

The reckoning day  for 2007 has now come and and also past for the FDA to review the rimonabant medication. Rimonabant is a medication known as well as Acomplia specialy in Europe,but also in other  states and Zimulti is the name that rimonabant has  in the United States. June 13th, the FDA vote was negative regarding the recommendasion of this rimonabant to hit the  pharmacies all over USA. What is  the meaning of this negative answer  for Sanofi-Aventis and what is going to happen with this medication in the future regarding the space of  the United States?
Rimonabant has been used in the past in many European states for  treating obesity. It works really different than much more other diet medications and it also  has some other benefits. Some of the possible benefits of this medication is that it  is increasing the “good” cholesterol,and in the same time is reducing “bad” cholesterol and it is possible in the future to  help smokers quit smoking . Basically speaking, Rimonabant is blocking receptors who are located in the brain and are responsible for food eagerness. When you’re eating less, it means,generally speaking that you are consuming less calories and that the conclusion is that you lose weight..

   Despite the fact that we don’t know all that happend on in the FDA meeting, we do know what were the discussions  that some that where brought up about this drug. One of the most important obstacles they had handlle it with  it’s the possible psychiatric side effects ,specially suicidal influences. The FDA panel was not satisfied with the amount off sideeffect and opinons they had regarding rimonabanr. Probably they will supervise it and that includes watching the feedback responses coming in from other doctors from all over the globe. It seems likely that a 50 month trail will then determine if this medication is going to be  accepted into the USA market, but this trail would not be complete until 2010. The FDA had been against for allowing drugs to hit the USA pharmacies also in the past, because they considered a too short of a study period. It seems that with such a possible popular medication such as acomplia or rimonant, that the FDA did not want to not know all aspects of this medication before they will accepted it in the USA.